Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
QuintilesIMS
Chinese Patent Office
Citi
Dow
McKinsey
US Department of Justice
Boehringer Ingelheim
US Army

Generated: June 25, 2018

DrugPatentWatch Database Preview

PRANDIN Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Prandin, and when can generic versions of Prandin launch?

Prandin is a drug marketed by Gemini Labs Llc and is included in one NDA.

The generic ingredient in PRANDIN is repaglinide. There are sixteen drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the repaglinide profile page.
Drug patent expirations by year for PRANDIN
Pharmacology for PRANDIN
Drug ClassGlinide
Mechanism of ActionPotassium Channel Antagonists
Synonyms for PRANDIN
(-)-Repaglinide
(+)-2-Ethoxy-alpha-(((S)-alpha-isobutyl-o-piperidinobenzyl)carbamoyl)-p-toluic acid
(s)-(+)-2-ethoxy-4-(2-oxo-2-[(alpha-isobutyl-2-piperidinobenzyl)amino]ethyl)-benzoic acid
(S)-(+)-2-Ethoxy-4-[N-[1-(2-piperidinophenyl)-3-methyl-1-butyl]aminocarbonylmethyl]benzoic acid
(S)-(+)-Repaglinide
(S)-2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)-phenyl)butyl)amino)-2-oxoethyl)-benzoic acid
(S)-2-Ethoxy-4-(2-((3-methyl-1-(2-(piperidin-1-yl)phenyl)butyl)amino)-2-oxoethyl)benzoic acid
(S)-2-Ethoxy-4-(2-((methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)-benzoic acid
(S)-2-ethoxy-4-(2-(3-methyl-1-(2-(piperidin-1-yl)phenyl)butylamino)-2-oxoethyl)benzoic acid
(S)-2-Ethoxy-4-[N-(1-(2-piperidino-phenyl)-3-methyl-1-butyl)-aminocarbonylmethyl]-benzoic acid
(S)-Repaglinide
111GE012
135062-02-1
2-ethoxy-4-({[(1S)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl]carbamoyl}methyl)benzoic acid
2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)benzoic acid
2-ethoxy-4-(2-{[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino}-2-oxoethyl)benzoic acid
2-ethoxy-4-[2-({(1S)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl}amino)-2-oxoethyl]benzoic acid
2-ethoxy-4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]benzoic acid
2-Ethoxy-4-[2-[[(1S)-3-Methyl-1-[2-(1-Piperidinyl)Phenyl]Butyl]Amino]-2-Oxoethyl]Benzoic Acid
2-ethoxy-4-[2-[[(1S)-3-methyl-1-[2-(1-piperidyl)phenyl]butyl]amino]-2-oxo-ethyl]benzoic acid
2-Ethoxy-4-{[(S)-3-methyl-1-(2-piperidin-1-yl-phenyl)-butylcarbamoyl]-methyl}-benzoic acid
2-ethoxy-N-(alpha-(2-methyl-1-propyl)-2-piperidinobenzyl)-4-carbamoylmethylbenzoic acid
62R021
668Z8C33LU
AB0013959
AB00514019
AB00514019_10
AB00514019_11
AB00514019-09
AB2000099
AC-726
AC1L24D5
AC1Q5TZW
Actulin
AG-EE 388
AG-EE 388 ZW
AG-EE 623 ZW
AG-EE 623ZW
AG-EE-388
AG-EE-623 ZW
AGEE-623ZW
AJ-45642
AK-59609
AKOS005561792
AM20090697
AN-15576
ANW-63956
API0004049
AX8145505
BC220160
BDBM50153520
Benzoic acid, 2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)-, (S)-
Benzoic acid, 2-ethoxy-4-[2-[[(1S)-3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]-
BG0514
BIDD:GT0338
Bio-0087
BPBio1_001070
BRD-K82846253-001-03-0
BS-1010
BSPBio_000972
C-22512
C07670
C27H36N2O4
CAS-135062-02-1
CC-34234
CCG-101013
CHEBI:8805
CHEMBL1272
CPD000466305
CS-0979
CTK3J7345
D00594
D0N5YA
DB00912
DR002802
DSSTox_CID_3552
DSSTox_GSID_23552
DSSTox_RID_77078
DTXSID3023552
enyglid
FAEKWTJYAYMJKF-QHCPKHFHSA-N
FT-0631150
Glaxo Wellcome brand of replaginide
GlucoNorm
GlucoNorm (TN)
GTPL6841
HE307690
HMS1571A14
HMS2051N08
HMS2094C07
HMS2098A14
HMS2231M21
HY-15209
I979
KS-00000GU9
LS-38509
MCULE-3611790330
MFCD00906179
MLS000759407
MLS001076684
MLS001424111
MLS006011560
MolPort-003-850-140
NC00263
NCGC00016978-01
NCGC00016978-02
NCGC00016978-04
NCGC00016978-05
NN-623
Novo Nordisk brand 2 of repaglinide
Novo Nordisk brand of repaglinide
NovoNorm
NovoNorm (TN)
NSC-759893
NSC759893
Pharmakon1600-01506035
Prandin (TN)
Prandin, GlucoNorm, NovoNorm, Repaglinide
Prandin;GlucoNorm;NovoNorm
Prestwick0_001046
Prestwick1_001046
Prestwick2_001046
Prestwick3_001046
Q-201663
R0179
Reglin
repa-glinide
Repaglinida
Repaglinida [INN-Spanish]
Repaglinide
Repaglinide (JAN/USP/INN)
Repaglinide [USAN:USP:INN:BAN]
Repaglinide [USAN]
Repaglinide for system suitability, European Pharmacopoeia (EP) Reference Standard
repaglinide, (+-)-isomer
Repaglinide, >=98% (HPLC), solid
Repaglinide, European Pharmacopoeia (EP) Reference Standard
Repaglinide, United States Pharmacopeia (USP) Reference Standard
Repaglinidum
Repaglinidum [INN-Latin]
RTC-063882
s1426
SAM001246546
SBI-0206942.P001
SC-17344
SCHEMBL16137
SMP-508
SMR000466305
SPBio_002906
ST24036034
STK629501
Surepost
Surepost (TN)
TC-063882
Tox21_110721
UNII-668Z8C33LU
W-5210
Z1777729210
ZINC3798537

US Patents and Regulatory Information for PRANDIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gemini Labs Llc PRANDIN repaglinide TABLET;ORAL 020741-001 Dec 22, 1997 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Gemini Labs Llc PRANDIN repaglinide TABLET;ORAL 020741-002 Dec 22, 1997 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Gemini Labs Llc PRANDIN repaglinide TABLET;ORAL 020741-003 Dec 22, 1997 AB RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for PRANDIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Gemini Labs Llc PRANDIN repaglinide TABLET;ORAL 020741-003 Dec 22, 1997 ➤ Sign Up ➤ Sign Up
Gemini Labs Llc PRANDIN repaglinide TABLET;ORAL 020741-003 Dec 22, 1997 ➤ Sign Up ➤ Sign Up
Gemini Labs Llc PRANDIN repaglinide TABLET;ORAL 020741-001 Dec 22, 1997 ➤ Sign Up ➤ Sign Up
Gemini Labs Llc PRANDIN repaglinide TABLET;ORAL 020741-002 Dec 22, 1997 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for PRANDIN
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Tablets 0.5 mg, 1 mg and 2 mg ➤ Subscribe 2005-02-10

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Covington
Fuji
Colorcon
Accenture
US Department of Justice
Baxter
Teva
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.